Bioeconomy Capital

Bioeconomy Capital is a company focused on investing in early-stage biotechnology firms to foster innovation within the sector. Leveraging extensive operational expertise and product development experience, it has created a proprietary blueprint aimed at building and deploying technological capabilities essential for the 21st-century economy. This blueprint reflects the combined expertise of its management team, which spans five decades in synthetic biology and engineering fields, making it a unique asset that is not easily replicated. The company's investment portfolio includes notable prior investments in firms such as Zymergen, Riffyn, Synthace, RoosterBio, Arzeda, Bellwether Bio, EdenWorks, and Lumen Biosciences, underscoring its commitment to advancing the biotechnology revolution.

Carlson, Rob

Managing Director and Co-Founder

16 past transactions

Parse Biosciences

Series C in 2023
Parse Biosciences is a biotechnology startup based in Seattle, Washington, that specializes in single-cell analysis. Founded in 2018 and rebranded from Split Biosciences in 2020, the company has developed innovative single-cell sequencing kit solutions that utilize combinatorial cDNA barcoding. This technology allows researchers to conduct experiments without the need for complex and costly microfluidic instruments. It also enables the fixation, freezing, and storage of samples, which separates sample extraction from downstream library preparation steps. As a result, researchers can analyze fixed samples collected on different dates in a single experiment, enhancing control over sample handling and minimizing errors. Additionally, Parse Biosciences’ technology improves gene detection in individual cells while reducing common confounding artifacts in single-cell sequencing, making it a valuable resource for researchers in the field.

Tandem PV

Series A in 2022
Tandem PV, Inc. is a manufacturer of advanced photovoltaic cells that combine perovskite and silicon technologies. Originally established as Iris Photovoltaics in 2016, the company rebranded in February 2018 and is headquartered in Palo Alto, California. Tandem PV specializes in mechanically-stacked perovskite and silicon tandem solar panels, which enhance solar panel efficiency significantly. By integrating metal-halide perovskite with existing silicon technology, Tandem PV aims to provide clients with improved performance and reduced installation costs, thereby increasing the overall value and market potential of solar energy.

Arzeda

Series B in 2022
Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that specializes in the development and manufacture of proteins and enzymes for various applications, including pharmaceuticals, polymers, and industrial chemicals. Founded in 2008, Arzeda utilizes advanced technology that combines physics-based protein design with artificial intelligence algorithms to create and validate new designer proteins and enzymes. The company aims to provide innovative solutions that offer competitive performance, cost efficiency, and sustainability, addressing the needs of clients in diverse industries.

Parse Biosciences

Series B in 2022
Parse Biosciences is a biotechnology startup based in Seattle, Washington, that specializes in single-cell analysis. Founded in 2018 and rebranded from Split Biosciences in 2020, the company has developed innovative single-cell sequencing kit solutions that utilize combinatorial cDNA barcoding. This technology allows researchers to conduct experiments without the need for complex and costly microfluidic instruments. It also enables the fixation, freezing, and storage of samples, which separates sample extraction from downstream library preparation steps. As a result, researchers can analyze fixed samples collected on different dates in a single experiment, enhancing control over sample handling and minimizing errors. Additionally, Parse Biosciences’ technology improves gene detection in individual cells while reducing common confounding artifacts in single-cell sequencing, making it a valuable resource for researchers in the field.

Parse Biosciences

Series A in 2021
Parse Biosciences is a biotechnology startup based in Seattle, Washington, that specializes in single-cell analysis. Founded in 2018 and rebranded from Split Biosciences in 2020, the company has developed innovative single-cell sequencing kit solutions that utilize combinatorial cDNA barcoding. This technology allows researchers to conduct experiments without the need for complex and costly microfluidic instruments. It also enables the fixation, freezing, and storage of samples, which separates sample extraction from downstream library preparation steps. As a result, researchers can analyze fixed samples collected on different dates in a single experiment, enhancing control over sample handling and minimizing errors. Additionally, Parse Biosciences’ technology improves gene detection in individual cells while reducing common confounding artifacts in single-cell sequencing, making it a valuable resource for researchers in the field.

Lumen Bioscience

Series B in 2020
Lumen Bioscience, Inc. is a biotechnology company based in Seattle, Washington, that focuses on developing therapeutic biologics for oral delivery. Founded in 2017, the company utilizes Spirulina, a blue-green algae, as a platform for the industrial-scale production of high-value molecules. Lumen Bioscience aims to create biologic drugs more efficiently than traditional methods, offering potential advancements in speed, scalability, and cost-effectiveness. The company serves various industries, including food, cosmetics, and healthcare, and is engaged in areas such as synthetic biology, protein design, immunology, bioreactor engineering, and cell physiology. By addressing prevalent diseases that currently lack effective treatments, Lumen Bioscience seeks to provide clinicians with innovative therapeutic options.

RoosterBio

Series B in 2019
RoosterBio, Inc. is a biotechnology company based in Frederick, Maryland, specializing in the development of mesenchymal stem cells (MSCs) for the regenerative medicine industry. Founded in 2012, RoosterBio focuses on providing human bone marrow-derived and adipose-derived MSCs designed for use by tissue engineers, cell therapists, and developers of technologies that integrate living cells. The company aims to accelerate advancements in regenerative medicine by simplifying and enhancing the research process, thereby enabling high-impact scientific exploration. RoosterBio has established strategic alliances with organizations such as Pall Corporation and Tissue Regeneration Therapeutics Inc. Through its innovative products, RoosterBio supports efforts to regenerate tissues and organs and addresses immune-related diseases.

MicroByre

Seed Round in 2019
MicroByre, Inc. is a biotechnology company based in Berkeley, California, founded in 2017. The company specializes in developing genetically tractable strains from non-model micro-species, focusing on the genetic engineering of bacteria for industrial applications. MicroByre has created a platform for bacterial domestication that utilizes an automated characterization pipeline to identify underutilized bacteria with favorable metabolic traits. These bacteria are capable of converting unrefined biomasses into commodity chemicals more efficiently than traditional fermentation processes. The company’s innovative approach involves minimal genetic modifications to enhance the bacteria's flexibility and yield, reduce the need for nutritional additives, and improve resistance to contamination and phage attacks. By bridging the gap between promising scientific advances and practical applications, MicroByre positions itself as a valuable partner for various industries, offering collaborative opportunities through service agreements or joint development projects.

Lumen Bioscience

Series A in 2017
Lumen Bioscience, Inc. is a biotechnology company based in Seattle, Washington, that focuses on developing therapeutic biologics for oral delivery. Founded in 2017, the company utilizes Spirulina, a blue-green algae, as a platform for the industrial-scale production of high-value molecules. Lumen Bioscience aims to create biologic drugs more efficiently than traditional methods, offering potential advancements in speed, scalability, and cost-effectiveness. The company serves various industries, including food, cosmetics, and healthcare, and is engaged in areas such as synthetic biology, protein design, immunology, bioreactor engineering, and cell physiology. By addressing prevalent diseases that currently lack effective treatments, Lumen Bioscience seeks to provide clinicians with innovative therapeutic options.

Synthace

Series A in 2017
Synthace Limited is a company focused on transforming the way biological experimentation is conducted across various sectors, including health, pharmaceuticals, food, energy, agri-science, and industrial biotechnology. Established in 2011 and headquartered in London, with an additional office in Cambridge, Massachusetts, Synthace offers a cloud-based platform called Antha. This platform enables life science research and development teams to streamline their experimental processes by allowing scientists to design, plan, and execute reproducible experiments without requiring coding skills. Antha facilitates the automation of laboratory experiments and the organization of experimental data, making it easier for researchers to run complex experiments that might have been previously deemed impractical. The company has also formed a strategic partnership with Microsoft to enhance its offerings.

Riffyn

Series A in 2017
Riffyn, Inc. is a company that specializes in developing a Software-as-a-Service platform for experimental process design and data analytics. Its primary product, Riffyn Nexus, is a cloud-based system that enhances research and development in various sectors, including life sciences, pharmaceuticals, food, and chemicals. By utilizing a process-centric approach, Riffyn Nexus enables users to visually design, measure, analyze, and collaborate on experiments, significantly improving the planning and learning cycle of scientific research. The platform integrates diverse scientific data in real-time, facilitating seamless data capture and analytics that support machine learning and artificial intelligence. This innovative system aims to accelerate development cycles and enhance productivity for R&D organizations globally. Founded in 2014 and headquartered in Oakland, California, Riffyn also provides implementation, change management, and educational services to its clients.

Arzeda

Series A in 2017
Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that specializes in the development and manufacture of proteins and enzymes for various applications, including pharmaceuticals, polymers, and industrial chemicals. Founded in 2008, Arzeda utilizes advanced technology that combines physics-based protein design with artificial intelligence algorithms to create and validate new designer proteins and enzymes. The company aims to provide innovative solutions that offer competitive performance, cost efficiency, and sustainability, addressing the needs of clients in diverse industries.

Riffyn

Venture Round in 2016
Riffyn, Inc. is a company that specializes in developing a Software-as-a-Service platform for experimental process design and data analytics. Its primary product, Riffyn Nexus, is a cloud-based system that enhances research and development in various sectors, including life sciences, pharmaceuticals, food, and chemicals. By utilizing a process-centric approach, Riffyn Nexus enables users to visually design, measure, analyze, and collaborate on experiments, significantly improving the planning and learning cycle of scientific research. The platform integrates diverse scientific data in real-time, facilitating seamless data capture and analytics that support machine learning and artificial intelligence. This innovative system aims to accelerate development cycles and enhance productivity for R&D organizations globally. Founded in 2014 and headquartered in Oakland, California, Riffyn also provides implementation, change management, and educational services to its clients.

Synthace

Venture Round in 2015
Synthace Limited is a company focused on transforming the way biological experimentation is conducted across various sectors, including health, pharmaceuticals, food, energy, agri-science, and industrial biotechnology. Established in 2011 and headquartered in London, with an additional office in Cambridge, Massachusetts, Synthace offers a cloud-based platform called Antha. This platform enables life science research and development teams to streamline their experimental processes by allowing scientists to design, plan, and execute reproducible experiments without requiring coding skills. Antha facilitates the automation of laboratory experiments and the organization of experimental data, making it easier for researchers to run complex experiments that might have been previously deemed impractical. The company has also formed a strategic partnership with Microsoft to enhance its offerings.

Synthace

Series A in 2014
Synthace Limited is a company focused on transforming the way biological experimentation is conducted across various sectors, including health, pharmaceuticals, food, energy, agri-science, and industrial biotechnology. Established in 2011 and headquartered in London, with an additional office in Cambridge, Massachusetts, Synthace offers a cloud-based platform called Antha. This platform enables life science research and development teams to streamline their experimental processes by allowing scientists to design, plan, and execute reproducible experiments without requiring coding skills. Antha facilitates the automation of laboratory experiments and the organization of experimental data, making it easier for researchers to run complex experiments that might have been previously deemed impractical. The company has also formed a strategic partnership with Microsoft to enhance its offerings.

Riffyn

Seed Round in 2014
Riffyn, Inc. is a company that specializes in developing a Software-as-a-Service platform for experimental process design and data analytics. Its primary product, Riffyn Nexus, is a cloud-based system that enhances research and development in various sectors, including life sciences, pharmaceuticals, food, and chemicals. By utilizing a process-centric approach, Riffyn Nexus enables users to visually design, measure, analyze, and collaborate on experiments, significantly improving the planning and learning cycle of scientific research. The platform integrates diverse scientific data in real-time, facilitating seamless data capture and analytics that support machine learning and artificial intelligence. This innovative system aims to accelerate development cycles and enhance productivity for R&D organizations globally. Founded in 2014 and headquartered in Oakland, California, Riffyn also provides implementation, change management, and educational services to its clients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.